Related Experiment Video
Updated: Aug 10, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Prevention of viral drug resistance by novel combination therapy
W F Mangel1, M T Brown, M L Baniecki
1Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA. Mangel@BNL.Gov
Abstract:
A new form of antiviral clinical therapy is proposed in which three different drugs are administered against three different targets on the same virus-coded protein. If the physiological functions of the three different target sites are not independent of each other, then a mutation conferring drug resistance at one site may alter the physiological functions at the other sites and further drug resistance may not arise. The adenovirus proteinase, with its two cofactors that act synergistically on enzyme activity, may be a good model system within which to test the efficacy of this form of combination therapy.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

